Stock Under $10 with 50-100% upside potential - 14 Days FREE!

J&J Recall Slideshow: The Recalls of 2011 & 2010

Stock quotes in this article: JNJ 

(J&J recall slideshow updated with company's latest medicine recall)

NEW YORK (TheStreet) -- Medicine recalls that greatly defined Johnson & Johnson (JNJ) last year continue to pester the company in 2011.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Most recently, J&J's McNeil Consumer Healthcare division said it was recalling certain lots of Tylenol 8 Hour, Tylenol Arthritis Pain and Tylenol upper respiratory products as a precautionary measure. The unit said it was also recalling certain lots of Benadryl, Sudafed and Sinutab products for the same reason. In addition, the division was recalling lots of Rolaids Multi-Symptom Berry Tablets.





It could almost be said that recalls defined consumer giant J&J in 2010, as its McNeil Consumer Healthcare division recalled tens of millions of packages of over-the-counter medicines that year, and the parent faced criminal investigation by the U.S. Justice Department as federal regulators became alarmed.

In turn, as the reputation of one of the world's most trusted names in consumer products became tarnished, shares of the company fell about 4% over the year, under-performing the S&P 500, which rose about 13% over the same time period. OTC drugs weren't the only products recalled by J&J in 2010; products from contact lenses to hip replacement products were also recalled.

TheStreet has compiled photos of major over-the-counter product recalls by J&J, creating a gallery that serves as a portrayal of J&J's yearlong market debacle last year -- and any other possible debacles in 2011. Read on for more ...

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs